Oncology
Latest news
826 articles · 20 / page
BL-B01D1, an EGFR–HER3 Bispecific ADC, Shows Promising Activity in Advanced Urothelial Carcinoma: Phase II Results
In a phase II single-arm study, BL-B01D1 demonstrated a 44.1% confirmed ORR and median PFS of 7.3 months at 2.2 mg/kg in patients with advanced urothelial carcinoma after prior systemic therapy, with predictable hematologic toxicity.
SMARCAL1 Emerges as a Novel Osteosarcoma Predisposition Gene: Large Study Validates DNA Repair Variation in Pediatric Cancer Risk
A large case-control analysis of 189 DNA damage response genes in nearly 6,000 children with cancer identifies enrichment of pathogenic variants in DDR genes and nominates SMARCAL1 as a replicated osteosarcoma predisposition gene
Starting Durvalumab with Chemoradiotherapy in Unresectable Stage III NSCLC Did Not Improve Outcomes: PACIFIC-2 Recalibrates the Timing of Immunotherapy
The phase III PACIFIC-2 trial found that giving durvalumab from the start of definitive concurrent chemoradiotherapy failed to improve progression-free or overall survival versus placebo; consolidation durvalumab after chemoradiotherapy rem
Hepatic Arterial Infusion of Floxuridine Plus Systemic Gemcitabine–Cisplatin Substantially Improves Survival for Liver‑Confined Unresectable Intrahepatic Cholangiocarcinoma: PUMP‑2 Trial Results
The PUMP‑2 phase II trial reports that hepatic arterial infusion (HAIP) of floxuridine combined with systemic gemcitabine–cisplatin achieved a 1‑year overall survival of 80% and median OS of 22.3 months in unresectable liver‑confined intrah
Ifinatamab Deruxtecan Shows Promising Activity in Previously Treated Extensive‑Stage SCLC: Primary Analysis of Phase II IDeate‑Lung01
In the phase II IDeate‑Lung01 trial, ifinatamab deruxtecan (I‑DXd) at 12 mg/kg every 3 weeks produced a confirmed ORR of 48.2% and median PFS 4.9 months in heavily pretreated extensive‑stage small cell lung cancer (ES‑SCLC), with an adjudic
Five-Year ZUMA-5 Follow-Up: Durable Remissions and Potential for Cure with Axicabtagene Ciloleucel in Relapsed/Refractory Follicular Lymphoma
Five-year outcomes from ZUMA-5 show axi-cel produces high response rates in relapsed/refractory indolent NHL, with 75% CR, median PFS ~62 months, durable remissions linked to early CAR T expansion and naïve T-cell product phenotype, and an
Encorafenib Plus Binimetinib in BRAF V600E-Mutant Metastatic NSCLC: Insights from the Phase II PHAROS Study and Updated Survival Outcomes
The Phase II PHAROS study demonstrates durable antitumor efficacy and manageable safety of encorafenib plus binimetinib in BRAF V600E-mutant metastatic NSCLC, with updated results showing the longest median overall survival reported for tar
Carboplatin in Neoadjuvant Chemotherapy for Triple‑Negative Breast Cancer: No EFS Gain but an Overall Survival Signal Driven by Premenopausal Patients
A phase III trial found that adding weekly carboplatin to taxane‑anthracycline neoadjuvant chemotherapy did not significantly improve event‑free survival overall but was associated with improved overall survival, with benefits concentrated
Longer Travel Time to Prostate Cancer Treatment Linked to Lower Mortality—Is Centralization the Explanation?
A large registry study found that men with prostate cancer who traveled ≥30 minutes to their treating facility had modestly lower all-cause and prostate cancer–specific mortality than those traveling
Neoadjuvant Pembrolizumab Plus Chemoradiotherapy Yields 43.2% pCR in Resectable ESCC — IL-6 Emerges as a Predictive Biomarker
The multicenter PALACE-2 trial reports a 43.2% pathological complete response (pCR) with preoperative pembrolizumab combined with chemoradiotherapy for resectable esophageal squamous cell carcinoma and identifies baseline serum IL-6 as a po
Radiotherapy Interruptions in Head and Neck Cancer Raise Risk of Locoregional Failure and Death — Impact Depends on p16 Status and Stage
Secondary analysis of three RTOG/NRG trials shows radiotherapy interruptions are associated with higher locoregional failure and worse overall survival in head and neck cancer, with larger absolute harms in p16‑negative and high‑stage disea
Long-Term Nirogacestat for Progressive Desmoid Tumors: Durable Responses, Continued Tumor Shrinkage, and a Manageable Safety Profile
Extended follow-up from the phase III DeFi trial shows that continuous nirogacestat yields further tumor shrinkage, durable objective responses (ORR 45.7% at up to 4 years), sustained patient-reported benefits, and a consistent, manageable
NCI Working Group on Biochemically Recurrent Prostate Cancer: Trial Design Guidance for a PSMA Era
The NCI convened experts to provide clinical-trial design recommendations for biochemically recurrent prostate cancer in the era of PSMA PET, defining PSMA+BCR, high-risk criteria, imaging and data standards, endpoint suggestions, and a pus
PASS-01: Gemcitabine/Nab‑Paclitaxel Shows an Overall Survival Edge Over Modified FOLFIRINOX in First‑Line Metastatic PDAC — Biomarker Correlatives Underscore Need to Move Precision Upstream
In the randomized phase II PASS‑01 trial of first‑line metastatic pancreatic ductal adenocarcinoma (PDAC), progression‑free survival was similar between modified FOLFIRINOX and gemcitabine/nab‑paclitaxel, but overall survival and safety tre
Eryaspase Fails to Improve Survival in Second‑Line Advanced Pancreatic Cancer: Results from the Phase III TRYBECA‑1 Trial
In TRYBECA‑1, adding erythrocyte‑encapsulated L‑asparaginase (eryaspase) to second‑line chemotherapy did not improve overall survival, progression‑free survival, or response rates in advanced pancreatic ductal adenocarcinoma; adverse events
Glecirasib, Alone and with Cetuximab, Shows Activity in KRASG12C-Mutant Colorectal Cancer — Combination Nearly Doubles Response Rate
Phase 1/2 data show oral glecirasib has single-agent activity (ORR 23%) in KRASG12C colorectal cancer; adding cetuximab raises ORR to 50% with manageable toxicity, supporting further randomized testing and earlier-line combination strategie
Zelenectide Pevedotin Shows Early Activity in Advanced Nectin‑4–Expressing Tumors, With Promising Responses in Urothelial Carcinoma
First-in-human dose-escalation data for zelenectide pevedotin (BT8009), a Nectin‑4–targeted Bicycle Drug Conjugate, demonstrate tolerability and preliminary efficacy (ORR 24% overall; 38% in urothelial carcinoma) supporting further evaluati
Chromosome 1q Gain, Not Lung Nodule Burden, Best Predicts Outcomes in Stage IV Favorable‑Histology Wilms Tumor
In AREN0533, number and size of pulmonary metastases had limited prognostic value after standardized therapy; gain of chromosome 1q emerged as a stronger, independent predictor of event‑free and overall survival in children with favorable‑h
Neoadjuvant 177Lu-PSMA Before SBRT Doubles Progression-Free Survival in Oligorecurrent Hormone-Sensitive Prostate Cancer — Results from the LUNAR Phase II Trial
In the randomized phase II LUNAR trial, adding two cycles of neoadjuvant 177Lu-PNT2002 to stereotactic body radiotherapy (SBRT) for oligorecurrent hormone-sensitive prostate cancer significantly prolonged progression-free survival (17.6 vs
Consensus Molecular Subtype 4 (CMS4) Identifies RAS Wild-Type mCRC Patients Who May Benefit Preferentially from Anti‑EGFR Therapy
An individual patient data meta-analysis of 790 RAS wild-type metastatic colorectal cancer patients suggests CMS4 tumors derive meaningful progression-free and overall survival benefit from anti‑EGFR versus anti‑VEGF antibodies, warranting
Browse by specialty
Open language-specific specialty feeds and department pages.